

**FORMULATION, DEVELOPMENT & CHARACTERIZATION OF
TRANSDERMAL PATCHES FOR CONTROLLED DELIVERY OF
METFORMIN HYDROCHLORIDE TO IMPROVE DRUG
BIOAVAILABILITY VIA TRANSDERMAL ROUTE**

Dr. Praveen Ashok, Dr. Yogita Tyagi, Hiba Parveen and Monu Kumar*

Gyani Inder Singh Institute of Professional Studies, Dehradun.

Article Received on
28 May 2024,

Revised on 19 June 2024,
Accepted on 09 July 2024

DOI: 10.20959/wjpr202414-33168



***Corresponding Author**

Monu Kumar

Gyani Inder Singh Institute
of Professional Studies,
Dehradun.

ABSTRACT

The main objective of this study was to formulate, develop and evaluate a Transdermal drug delivery system containing Metformin hydrochloride to overcome the critical problems related with oral route. Transdermal patch of Metformin hydrochloride were prepared using solvent evaporation technique. Different trial of formulation were carried out by changing the polymer ratio. Transdermal Patch formulations were characterized for Thickness, weight variation, Percentage Moisture content, Folding endurance, Assay and In vitro drug release studies. The purpose of this research was to determine whether or not the polymeric combinations of HPMC and ethyl cellulose could be used to create an effective matrix-type transdermal drug delivery system (TDDS) of MetforminHCL (EC). In a solvent system of dichloromethane and methanol (1:1), 6 matrix patches were

produced employing these polymeric materials with propylene Glycol as a plasticizer and vegetable oils (eucalyptus oil) as permeation enhancers. Weight, medicament content, water content, hydration uptake, flatness, folding durability, and thickness were all measured and analysed to describe the formulations. Scanning electron microscopy (SEM) of the generated TDDS were recorded to see the drug - delivery pattern, and the stability of the preparations and in vitro dissolution of the trial formulations were utilized to calculate the quantity of metformin HCL in the patches.

KEYWORDS: Transdermal Delivery, Metformin Hydrochloride, Topical Drug Delivery.

INTRODUCTION

Oral medication administration is widespread and simplifies administration. Poor bioavailability owing to hepatic first-pass metabolism and fast blood level fluctuations (both high and low) require high and/or frequent dosing, that is unpleasant. For these problems, a novel medicine delivery mechanism is needed. Transdermal medication delivery uses self-contained, discrete dose forms that, when applied to undamaged skin, transfer the drug to the systemic circulation. TDDS is a key feature of new drug delivery systems.^[1] Transdermal medication administration improves bioavailability and action time, reducing dose frequency. Reduced side effects, and if toxicity occurs, the patch can be removed. Topical patches give drugs painlessly and noninvasively. This route delivers medications more effectively than oral, parenteral, etc., which are broken down by stomach acids, poorly absorbed by the gut, or destroyed by the liver. Long-term stabilization of blood levels.^[2] They are Non-invasive and cause prevention of parenteral therapy. They improve compliance by extending therapy with a single application. More frequent dosing with other dosage types. Short-half-life medicines' action is extended via a drug reservoir and regulated release. Eliminating a drug from the skin can end treatment quickly. Its physicality, characteristics, and distinguishing marks make them simple to recognize in crises (e.g., inattentive, unconscious, or coma patient).^[3] Improve therapy efficacy by reducing inter- and inpatient variance.

Disadvantage

Topical site discomfort is possible. Drug, adhesive, or other patch excipients might produce erythema, irritation, and local edema. Large drug molecules hinder absorption. Ideal medication molecule size is 800-1000 Daltons. Many hydrophilic medicines have slow skin permeability and therapeutic effect. Transdermal delivery works well with lipophilic drugs. The skin's barrier function varies from one individual to the next, and with age. Transdermal medication delivery can't achieve maximum blood/plasma levels. Since patches are small, drug molecules should be powerful. Discomfort and hypersensitivity are possible.^[4] ^[5] No medications which need high blood levels could be given.

The Transdermal drug delivery system designed by various methods such as transdermal patches includes matrix, micro reservoir, reservoir, adhesive, and membrane matrix hybrid. Matrix type transdermal patches are most popular as they are easy to construct. The metformin hydrochloride transdermal patch in this paper also developed by using the Matrix type of transdermal drug delivery system. Metformin hydrochloride is the anti-diabetic agent having

the low molecular weight water soluble drug. The daily dosage of transdermal delivered metformin in between 5 and 500 mg per day.^[6]

Table 1: Drug polymer composition for interaction study.

Sr. No	Material	Drug polymer Ratio	40 °C/75%RH
1	Metformin Hydrochloride	1:0	3 weeks
2	Metformin Hcl + HPMC	1:1	3 weeks
3	Metformin Hcl + Ethyl cellulose	1:1	3 weeks
4	Metformin Hcl + Ethyl cellulose+ HPMC	1:1:1	3 weeks

MATERIAL AND METHODS

Materials such as HPMC, dibutyl phthalate, and metformin hydrochloride have been procured from the institute. Analytical grade materials also employed for all other compounds and solutions in the study.

Methods

Metformin HCL Calibration Curve in 7.4 Phosphate Buffer.

1) 7.4 phosphate buffer preparation

50mL of 0.2 M Potassium Dihydrogen Phosphate should be combined with 39.1 mL of 0.2 M Sodium Hydroxide and vol. 200mL makeup.

2) Stock Solution preparation

Take 100 milligrams of metformin HCl in a 100 mL volumetric flask and combine it with enough phosphate buffer. then add phosphate buffer upto 100 mL for vol. makeup. Now, take 10 mL out from previously mentioned solution, make it up to 10 g/mL (stock solution), add 0.1 mL, 0.3 mL, 0.4 mL, 0.5 mL, 0.6 mL, and 0.7 mL to 10 phosphate buffer, and then perform spectrophotometric analysis at 232 nm using 7.4 buffer solution as a blank. and after that, observations were noted.

3) Phosphate buffer preparation with pH 7.4

Properly quantified, in a 200 mL volumetric flask, we mixed 50 mL of 0.2 M potassium dihydrogen orthophosphate with 39.1 mL of 0.2 M sodium hydroxide. Distilled water was added to bring the total volume to 200 mL; the mixture then is stirred and the pH was altered to 7.4 using 0.2 M sodium hydroxide.

4) 0.2 M potassium dihydrogen phosphate solution preparation

Monobasic potassium dihydrogen phosphate, precisely weighed at 27.218 g, then diluted in 1000 ml of purified water and combined.

5) 0.2 M sodium hydroxide solution preparation

8 g of sodium hydroxide pellets that had been precisely measured then diluted in 1000 millilitres of distilled water and blended.

METHODOLOGY**Transdermal Patches of Metformin Hydrochloride preparation**

In a solvent system consisting of an equal volume of methanol and dichloromethane (1:1), ethylcellulose and PVP K-30 were dissolved together with metformin HCL (20% w/w of the dry mass of the polymer), propylene glycol (30% w/w) as a plasticizer, and eucalyptus oil (2%, 5%, and 7%) as a permeation enhancer to produce a polymeric At first, the solution was prepared by utilising a number of different polymeric mix ratios; however, a permeation enhancer was not included in the process. The ingredients for the transdermal patches were generated by following the technique that had been explained earlier with varying polymer concentrations, and the patches were then stirred on a magnetic stirrer for forty-five minutes to make an even mixture. After combining the drug and the polymer, the resulting solution was mixed into a glass ring that was placed on a Petri plate that contained a mercury pool. The mixture was then let to stand for 15 minutes in order to remove any air bubbles that may have formed. In order to produce the drug-polymer matrix patch, the solvent was allowed to evaporate at a temperature of 40 degrees Celsius for twenty-four hours.^[7] After a period of twenty-four hours, the patch was recovered and stored in a desiccator until it was required once more. In the preparations, HPMC E50 was used as a release retardant, and PVP K30 was used as a polymer. Both of them were made with PVP. Methanol and dichloromethane were utilised in this process as the solvents of choice. Dibutyl phthalate was utilised in this process in the capacity of a plasticizer.^[8,9]

Physical appearance

The colour, clarity, flexibility, and smoothness of each created patch have all been checked.

RESULT

The emergence of the films demonstrated their formation. Due to the use of propylene glycol, a plasticizer that assisted in the manufacture of flexible films, patches were discovered to be

offwhite in colour, smooth, clear, and soft.

Patch Thickness

A digital micrometre is used to determine the thickness of the drug-loaded patch at various sites, which yields the average thickness.

Flatness

Three longitudinal strips, one from the centre, one from the left, and one from the right, were cut out of each film. Each strip's length is calculated, and the difference in length due to non-uniformity in flattening was assessed using a percent constriction measurement, where 0% constriction is equivalent to 100% flatness.^[10]

$$100\% \text{ constriction} = I_1 - I_2 - I_3$$

where I_1 is the starting length for each strip, I_2 is the total length of each strip.

Folding Endurance

It was assessed by repeatedly folding a single film until it split. The measure of folding endurance is determined by how many times a film can be folded within the same location without breaking or cracking.

Percentage of Moisture Content

Each film was weighed and maintained in an activated silica-filled desiccator over 24 hours at room temperature.

Each film is measured until they emerged as consistent. The difference among first and last weights in relation to total mass was used to compute the % of moisture content.^[11]

$$\text{Percentage of moisture content} = \frac{(X - Y)}{Y} \times 100$$

X = initial weight, Y = final weight.

Moisture Uptake

The patches were assessed, dried in a vacuum desiccator at room temperature for 24 hours, and then subjected to 84% relative humidity (potassium chloride solution).

$$(Y - X/X) \times 100 = \% \text{ moisture absorption}$$

X = initial weight, Y = final weight.^[12]

Drug content study

Using pH 7.4 phosphate buffer, drug content was studied. 1 cm² patches were crumbled and placed in a 100 ml volumetric flask. 5 hours of stirring with a teflon-coated magnetic bead. The supernatant was UV spectrophotometer tested for drug concentration at 233 nm.

Weight Variation

Each formulation had three randomly picked patches. 3 films out of each batch were examined individually to determine weight variation.

Scanning electron microscope

SEM studies drug and polymer distribution in the film. Every sample was sliced and fixed on stubs with double-sided tape for this experiment. Employing fine coat ion sputter, the sections are plated with gold-palladium alloy to make them conductive. The portions are then SEM- examined.^[13]


Patches with varying polymer concentrations (no permeation enhancer). Patch release profiles with 2%, 5%, and 7% Eucalyptus oil polymers.

Table 1: Calibration Curve of metformin

Absorbance data for calibration curve of Metformin HCl in 7.4 Phosphate buffer metformin HCl in phosphate.

Conc. (µg/ml)	Abs
0	0
0.5	0.091
1	0.169
3	0.341

5	0.561
7	0.768
8	0.996



Absorbance data for calibration curve of Metformin HCL in water.

RESULT AND DISCUSSION

A hydrophilic polymer such as HPMC and a hydrophobic polymer such as EC were employed in the preparation of the transdermal patches for MFH by a technique known as

solvent evaporation. The purpose of the study was to develop once-daily delivery systems for MFH. To do this, a variety of various combinations of the aforementioned polymers were used, with the drug concentration remaining the same across all formulations. Evaluation of six different transdermal patches, including folding endurance, uniformity of thickness, moisture content and moisture uptake, percent flatness study, weight variation study, drug content study, and folding endurance of all the different formulations is shown in the table. Folding endurance of transdermal patches. It was discovered that the thicknesses of the films that were created could be characterised. There was a continuous decrease in thickness despite there being an increase in the amount of HPMC.^{[14] [15]} Therefore, it is clear from the results that EC contributes to increasing the thickness of the layer.

The amount of moisture contained in each formulation as well as its capacity to absorb moisture. When there is a higher concentration of hydrophilic polymer, there is a corresponding increase in the moisture content, and when there is a higher concentration of hydrophobic polymer, there is a corresponding reduction. It was discovered that FC8 had the lowest amount of moisture content of all the patches. When the concentration of hydrophilic polymer increases, the moisture uptake increases as well. On the other hand, the moisture uptake decreases when the concentration of hydrophobic polymer increases. It was discovered that FC8 showed the least amount of moisture uptake among all of them. Data regarding the percent flatness of the patches that were prepared. It was clear that there was not a significant amount of variation in the flatness shows homogenous regions. The data on the weight variation of all of the patches demonstrated that there were no major variations across the patches, and the deviation was acceptable within the parameters set. The proportion of active ingredient found to vary from 94.23 to 96.48, which is acceptable, particularly in FC4 and FC7, was determined to be within this range. It shows that there was no substantial difference between the patches in a single set, and that the deviation was acceptable given the parameters. The amount of substance discovered in the sample ranged from 94.23 percent all the way up to 95.99 percent. It shows that there was no major loss of the drug throughout the formulation and processing of the material, and it also shows that the product is suitable for providing the appropriate therapeutic effect. The tensile strength of the patches dramatically reduces as the amount of hydrophilic polymer used in the patches increases, yet this is not the case. It was discovered that there was a significantly significant variance in the percentage of elongation across the various proportions of the polymers that were utilised. In comparison to the results of the other formulations, Formulation FC8 demonstrated a high tensile strength

and a lower percentage of elongation. It is abundantly clear from the infrared spectra that there were no interactions between the medication and the polymer.

There is not a discernible change in the magnitude of the primary peak in the spectra of the medication MFH when it is either free or combined with polymer. Infrared spectra have revealed that there is a peak at 1688.48, which indicates the presence of a C=N functional group that stretches. The occurrence of a peak at 1254.14, which indicates that C-N stretching is taking place, is seen. The presence of carbon-hydrogen bonds is shown by a peak at 1473.34. (Bend in the plane). Concurrently, a peak at 732.97 indicates the presence of N-H functional group.


Physical Interaction Study

Visual interaction study were carried out there is no any visual difference observed. All polymers shows physical compatibility with drug.

Sr. No	Material	Initial observation	observation after 3 Weeks
1	Metformin Hydrochloride	White powder	White powder
2	Metformin Hcl + HPMC	White powder	White powder
3	Metformin Hcl + Ethyl cellulose	White powder	White powder
4	Metformin Hcl + Ethyl cellulose+ HPMC	White powder	White powder

In-vitro Drug Release

Transdermal patches of all formulation was evaluated for drug release profile formulation F7 showing good sustained release profile upto 12 hrs. Cumulative drug release after 12 hrs was observed 96.12%.



In-vitro Drug Release profile of Formulations

CONCLUSION

The objective of this study was to ascertain the feasibility of utilising the polymeric blends of HPMC and ethyl cellulose for the development of a proficient matrix-based transdermal drug delivery system for Metformin HCL. Using a solvent system consisting of dichloromethane and methanol, six matrix patches were created. These patches were made using polymeric materials, with propylene glycol serving as a plasticizer and vegetable oils acting as permeation enhancers. The formulations were evaluated and described based on measurements of weight, medicament content, water content, hydration uptake, flatness, folding durability, and thickness. On the basis of results obtained in this study, it can be concluded that formulation of metformin transdermal patches employing two polymers fusion can be the efficient formulation.

The prepared transdermal patch consists of the ethyl cellulose and HPMC as a polymer, this combination of polymer was found to maintain the sustained release effect of the transdermal. PEG 400 used as plasticizer in the patch it produces good flexibility. It does not produce any irritation at the site of application because of flexible and soft surface. Metformin hydrochloride containing transdermal drug delivery is very better for topical route. It may improve compliance of patient those unable to take drug orally.

REFERENCES

1. Selvam R. P, Singh A.K, Sivakumar T.(2010). Transdermal drug delivery systems for antihypertensive drugs - A review, International Journal of pharmaceutical and biomedical research, 1(1): 1-8.
2. Scarbrough et al. (2012) Transdermal Delivery of Metformin-Patent, United States Patent Application Publication, US 20120283332A1
3. Jadhav R.T, Kasture P.V, Gattani S.G, Surana S.J.(2009). formulation and evaluation of transdermal Films of diclofenac sodium, International Journal of PharmTech Research, 1(4): 1507-1511.
4. Mallesh K, Srinivas C, Nagasree K, Prakash VD. Formulation and Evaluation of Prednisolone Proliposomal Gel for Effective Topical Pharmacotherapy. IJPSSDR, 4(1): 2012, 35-43.
5. Ljeoma FU. Synthetic surfactant vesicles niosomes and other non-phospholipid vesicular systems. Publisher: CRC Press, 2000.
6. Janga KY, Jukanti R, Velpula A. Bioavailability enhancement of Zaleplon via

- proliposomes: Role of surface charge. *Euro JPharm and Biopharm*, 2012; 80(2): 347-357.
7. Ravi TA, Hemant KS Yadav, Swetha S, Sarat Chandra Prasad M. Preparation and evaluation of transdermal patches of Metformin hydrochloride using natural polymer for sustained release. *Int J Pharm Pharm Sci*, 2012; 4(13): 297-301.
 8. Bhavesh D, Chetan G, Bhat KM. Shivprakash. Estimation and pharmacokinetic of Metformin in human volunteers. *Ind JPharm Edu Res*, 2002; 41(2): 15-139.
 9. Hwang BY, Jung BH, Chung SJ, Lee MH, Shim CK. In vitro skin permeation of nicotine from proliposomes. *J Control Release*, 1997; 49: 177-184.
 10. Mallesh K, Nikitha P, Ranjith K, Pratap C. Piroxicam proliposomal gel -A novel approach for topical delivery. *J Pharm Res*, 2012; 5(3): 1755-1763.
 11. Shivalingam MR, Vineela A, Vaishnavi K, Sunanda C, Prince VA, Jyotsna S. Formulation and evaluation of pantaprazole transdermal patches for enhanced therapeutic efficacy. *Int J Pharm Biomed Res*, 2015.
 12. Gupta R, Bajpal M and Bhattacharya A. Formulation and in vitro Evaluation of transdermal drug delivery system of tizanidine hydrochloride, *Indian J. Pharm. Sci*, 2008; 7(4): 208-13.
 13. Gupta SP, Jain SK. Effective and controlled transdermal delivery of metoprolol tartarate. *Indian Journal of pharmaceutical sciences*, 2005; 67(3): 346.
 14. Saxena M, Mutalik S, Reddy MS. Formulation and evaluation of transdermal patches of metoclopramide hydrochloride. *Indian drugs*, 2006; 43(9): 740-5.
 15. Mundargi RC, Patil SA, Agnihotri SA, Aminabhavi TM. Evaluation and controlled release characteristics of modified xanthan films for transdermal delivery of atenolol. *Drug development and industrial pharmacy*, 2007 Jan 1; 33(1): 79-90.